<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061837</url>
  </required_header>
  <id_info>
    <org_study_id>XJ-20190823</org_study_id>
    <nct_id>NCT04061837</nct_id>
  </id_info>
  <brief_title>MitralStitch Mitral Valve Repair System for Mitral Regurgitation</brief_title>
  <official_title>To Evaluate the Effectiveness and Safety of MitralStitch Mitral Valve Repair System - a Clinical Application of New Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the effectiveness and safety of the MitralStitch repair
      system in patients with moderate to severe and severe mitral regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence rate of major adverse event after 30 days of the intervention</measure>
    <time_frame>30days</time_frame>
    <description>The occurrence of complications associated with any device or operation, including but not limited to: death, emergency surgery, severe pericardial tamponade requiring pericardiac puncture or surgery, bleeding, and surgically related stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The success of device</measure>
    <time_frame>Immediately after repair</time_frame>
    <description>The MitralStitch mitral valve repair system reaches the mitral valve and implant the chord and withdraw the system successfully.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of operation</measure>
    <time_frame>Before discharge, an average of 7 days</time_frame>
    <description>Mitral regurgitation was less than moderate before discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse events after device implantation</measure>
    <time_frame>12months</time_frame>
    <description>There were no major adverse events associated with device or operation within 12 months of device implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The classification of mitral regurgitation</measure>
    <time_frame>1/6/12 months</time_frame>
    <description>Mild: No mitral regurgitation or the centricity regurgitation area is smaller than the 20% of left atrial area.
Moderate: The area of centricity regurgitation is upper than 40%, lower than 60% of the left atrial area; VC≥0.7cm; regurgitant volume≥60ml； RF≥50%; EROA≥0.4cm².
Severe: The area of centricity regurgitation is upper than 40% of the left atrial area or systolic eccentric regurgitation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>MitralStitch repair system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitralStitch</intervention_name>
    <description>With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System</description>
    <arm_group_label>MitralStitch repair system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The age of patient is ≥18yrs;

          2. Severe mitral regurgitation patients (The area of central regurgitation exceeds 40% of
             left atrial area or holosystolic eccentric regurgitation; VC≥0.07cm；regurgitant volume
             ≥60ml；RF ≥50%; EROA≥0.4cm2 (Satisfy any condition).

          3. LVESD≤60mm, LVEF≥25%, small incision surgery of chest can be tolerated.

          4. The subject was informed of the clinical application nature of the new technology and
             agreed to participate in all requirements of the clinical application of the new
             technology, signed the ICF and agreed to complete the follow-up and the inspection
             required during the follow-up period.

        Exclusion Criteria:

          1. Subject who are pregnant, lactating or scheduled to pregnant during the period of the
             clinical new technology.

          2. Subjects with active endocarditis or rheumatic mitral valve disease.

          3. Life expectancy &lt;1 year for cardiac or other malignant tumors.

          4. Participate in other clinical trial

          5. In the judgment of the investigator, subjects had poor acceptance of chemotherapy, and
             they cannot complete the trial as required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiqiang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Yang</last_name>
    <role>Study Director</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Surgery of Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Jian Yang</investigator_full_name>
    <investigator_title>Deputy chief surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

